KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2025)

Aquestive Therapeutics has reported Non-Current Debt over the past 9 years, most recently at $27.5 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $27.5 million for Q4 2025, down 15.33% from a year ago — trailing twelve months through Dec 2025 was $27.5 million (down 15.33% YoY), and the annual figure for FY2025 was $27.5 million, down 15.33%.
  • Non-Current Debt for Q4 2025 was $27.5 million at Aquestive Therapeutics, down from $29.9 million in the prior quarter.
  • Over the last five years, Non-Current Debt for AQST hit a ceiling of $51.6 million in Q4 2021 and a floor of $16.1 million in Q1 2024.
  • Median Non-Current Debt over the past 5 years was $32.6 million (2021), compared with a mean of $32.9 million.
  • Biggest five-year swings in Non-Current Debt: plummeted 52.53% in 2023 and later surged 109.36% in 2025.
  • Aquestive Therapeutics' Non-Current Debt stood at $51.6 million in 2021, then crashed by 35.12% to $33.4 million in 2022, then decreased by 17.76% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then fell by 15.33% to $27.5 million in 2025.
  • The last three reported values for Non-Current Debt were $27.5 million (Q4 2025), $29.9 million (Q3 2025), and $31.8 million (Q2 2025) per Business Quant data.